Erratum to the article "Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers" by Noushin Brealey, Ashutosh Gupta, Jessica Renaux, Rashmi Mehta, Ann Allen, and Alex Henderson in *International Journal of Clinical Pharmacology and Therapeutics,* Vol. 53 -- No. 9/2015, pp 753-764.

Following an ad hoc review of our paper, we noticed some incorrect data in some of the tables. Upon further investigation it became clear that when Tables 1, 2a and b, 3a and b, 4a and b, and 6 were reproduced for the clinical study report and subsequently copied into our published paper, a number of transcription errors were inadvertently included. An additional QC of the data from the source studies, CTT116415 and 200587, has revealed these were the only errors in the published paper.

We would like to highlight that despite these errors being included in our original report, the conclusions from study CTT116415 and study 200587 remain unaffected and valid as stated in the manuscript. This is because our statistical conclusions and treatment comparisons are based on the 90% confidence interval of treatment ratio estimates (Table 5b on page 759 of the publication), which is not affected by these amends.

We would like to apologize for this unfortunate error.

*Alex Henderson, on behalf of all authors*

The errors have been corrected as follows and highlighted in red/strikethrough (incorrect data) and green (correct data).

###### Participant characteristics and demographics.

  ---------------------------------------------------------------------------------------------------
                                              Study 1 CTT116415 (n = 44)   Study 2 200587 (n = 44)
  ------------------------------------------- ---------------------------- --------------------------
  Mean age, years (range)                     36.5 (20 -- 56)              39.1 (19 -- 66)

  Sex, n (%)\                                 \                            \
    Male\                                     32 (73)\                     36 (82)\
    Female                                    12 (27)                      ~~*5 (11)*~~ **8 (18)**

  BMI, kg/m^2^ (range)                        27.7 (21.1 -- 33.3)          N/A

  Ethnicity, n (%)\                           \                            \
    Hispanic or Latino\                       4 (9)\                       ~~*8 (18)*~~ **5 (11)**\
    Other                                     40 (91)                      39 (89)

  Race, n (%)\                                \                            \
    African American/African heritage\        38 (86)\                     34 (77)\
    American Indian/Alaskan Native\           1 (2)\                       1 (2)\
    Native Hawaiian/Other Pacific Islander\   1 (2)\                       0\
    White (Arabic/North African heritage)\    0\                           1 (2)\
    White (Caucasian/European heritage)       4 (9)                        8 (18)
  ---------------------------------------------------------------------------------------------------

BMI = body mass index.

Table 2a.FF Plasma PK summary in study 1 (CTT116415).ParameterTreatment^a^NnGeometric mean\
(95% CI)%CVbAUC~(0--8)~ (h×pg/mL)FF/UMEC/VI4343383 (357 -- 410)23.0FF/UMEC4342366 (333 -- 402)30.6FF/VI4242322 (298 -- 348)25.5AUC~(0--t)~ (h×pg/mL)FF/UMEC/VI4343882 (774 -- 1,005)44.3FF/UMEC4342765 (653 -- 897)54.4FF/VI4242662 (570 -- 768)50.7C~max~ (pg/mL)FF/UMEC/VI434379.4 (71.7 -- 88.0)34.2FF/UMEC434279.2 (71.0 -- 88.3)36.2FF/VI424263.6 (58.0 -- 69.6)29.9t~1/2~ (h)^~~*b*~~^FF/UMEC/VI432921.6 ~~*(17.2, 27.1)*~~ **(17.2 -- 27.1)**65.0FF/UMEC432920.7 ~~*(16.7, 25.7)*~~ **(16.7 -- 25.7)**62.2FF/VI422522.4 ~~*(17.6, 28.3)*~~ **(17.6 -- 28.3)**62.5t~max~ (h)^b^FF/UMEC/VI43430.2 (0.1, 2.0)NAFF/UMEC43420.5 (0.1, 2.0)NAFF/VI42421.0 (0.1, 2.1)NAt~last~ (h)^b^FF/UMEC/VI434336.0 (8.0, ~~*48.2*~~ **48.3**)NAFF/UMEC434236.0 (8.0, 48.2)NAFF/VI424224.0 (8.0, 48.1)NA[^1]

Table 2b.FF plasma PK summary in study 2 (200587).ParameterTreatment^a^NnGeometric mean\
(95% CI)%CVbAUC~(0--4)~ (h×pg/mL)FF/UMEC(500)/VI4444212 (196 -- 229)26.0FF/UMEC(250)/VI4343211 (192 -- 232)31.8FF/VI4343219 (200 -- 239)29.6AUC~(0--t)~ (h×pg/mL)FF/UMEC(500)/VI4444629 (555 -- 713)43.2FF/UMEC(250)/VI4343607 (525 -- 702)49.9FF/VI4343644 (566 -- 732)43.8C~max~ (pg/mL)FF/UMEC(500)/VI4444~~*81.4*~~ **81.5** (73.3 -- 90.6)35.9FF/UMEC(250)/VI434381.1 (72.2 -- ~~*91.0*~~ **91.1**)39.1FF/VI434385.7 (76.6 -- 95.8)37.6t~max~ (h)^b^FF/UMEC(500)/VI4444~~*0.2*~~ **0.3** (\< 0.1, 2.0)NAFF/UMEC(250)/VI4343~~*0.2*~~ **0.3** (\< 0.1, 2.0)NAFF/VI43430.2 (\< 0.1, 2.0)NAt~last~ (h)^b^FF/UMEC(500)/VI444424.0 (4.0, 24.1)NAFF/UMEC(250)/VI434324.0 (~~*8.0*~~ **6.0**, 24.1)NAFF/VI434324.0 (8.0, 24.1)NA[^2]

Table 3a.UMEC plasma PK summary in study 1 (CTT116415).ParameterTreatment^a^NnGeometric mean\
(95% CI)%CVbAUC~(0--4)~ (h×pg/mL)FF/UMEC/VI4343494 (459 -- 531)23.9FF/UMEC4342498 (461 -- 537)24.9UMEC/VI4141502 (463 -- 544)26.1AUC~(0--t)~ (h×pg/mL)FF/UMEC/VI4343885 (785 -- 997)40.3FF/UMEC4342797 (712 -- 893)37.6UMEC/VI4141931 (810 -- 1,070)46.2C~max~ (pg/mL)FF/UMEC/VI43431,189 (1,015 -- 1,392)54.9FF/UMEC43421,099 (950 -- 1,271)49.2UMEC/VI41411,217 (1,016 -- 1,459)62.4t~1/2~ (h)^~~*b*~~^FF/UMEC/VI431224.6 ~~*(12.0, 50.4)*~~ **(12.0 -- 50.4)**~~*161*~~ **160.5**FF/UMEC431914.3 ~~*(8.0, 25.4)*~~ **(8.0 -- 25.5)**~~*179*~~ **178.6**UMEC/VI411517.8 ~~*(8.5, 37.4)*~~ **(8.5 -- 37.4)**~~*224*~~ **223.8**t~max~ (h)^b^FF/UMEC/VI43430.1 ~~*(0.1, 0.2)*~~ **0.1, 0.3)**NAFF/UMEC43420.1 ~~*(0.1, 0.2)*~~ **0.1, 0.3)**NAUMEC/VI41410.1 (0.1, 0.3)NAt~last~ (h)^b^FF/UMEC/VI434336.0 (8.0, 48.1)NAFF/UMEC434224.0 (4.0, 48.2)NAUMEC/VI414136.0 (6.0, 48.3)NA[^3]

Table 3b.UMEC plasma PK summary in study 2 (200587).ParameterTreatment^a^NnGeometric mean\
(95% CI)%CVbAUC~(0--2)~ (h×pg/mL)FF/UMEC(500)/VI4444423 (383 -- 467)33.3FF/UMEC(250)/VI4343205 (186 -- 225)31.6UMEC(250)/VI4343204 (186 -- 222)29.3AUC~(0--t)~ (h×pg/mL)FF/UMEC(500)/VI4444770 (688 -- 862)38.4FF/UMEC(250)/VI4343323 (282 -- 369)45.6UMEC(250)/VI4343310 (275 -- 349)40.4C~max~ (pg/mL)FF/UMEC(500)/VI44441,098 (910 -- 1,326)68.3FF/UMEC(250)/VI4343~~*540*~~ **539** (443 -- 657)71.1UMEC(250)/VI4343549 (463 -- 651)59.9t~1/2~ (h)^~~*b*~~^FF/UMEC(500)/VI44154.1 ~~*(2.7, 6.2)*~~ **(2.7 -- 6.2)**87.5FF/UMEC(250)/VI43222.3 ~~*(2.0, 2.6)*~~ **(2.0 -- 2.6)**31.6UMEC(250)/VI43292.3 ~~*(2.1, 2.6)*~~ **(2.1 -- 2.6)**27.4t~max~ (h)^b^FF/UMEC(500)/VI4444\< 0.1 (\< 0.1, 0.2)NAFF/UMEC(250)/VI4343**\<** 0.1 (\< 0.1, 0.1)NAUMEC(250)/VI4343**\<** 0.1 (\< 0.1, 0.2)NA[^4]

Table 4a.VI plasma PK summary in study 1 (CTT116415).ParameterTreatment^a^NnGeometric mean\
(95% CI)%CVbAUC~(0--2)~ (h×pg/mL)FF/UMEC/VI4343307 (289 -- 327)19.9FF/VI4242260 (247 -- 274)17.1UMEC/VI4141264 (247 -- 282)20.9AUC~(0--t)~ (h×pg/mL)FF/UMEC/VI4343522 (482 -- 565)26.4FF/VI4242462 (424 -- 504)28.5UMEC/VI4141439 (401 -- 481)29.4C~max~ (pg/mL)FF/UMEC/VI4343639 (586 -- 696)28.6FF/VI4242442 (412 -- 474)22.8UMEC/VI4141486 ~~*(445 -- 514)*~~ **(445 -- 532)**28.8t~1/2~ (h)^~~*b*~~^FF/UMEC/VI43398.6 ~~*(7.4, 10.0)*~~ **(7.4 -- 10.0)**49.7FF/VI42389.0 ~~*(7.4, 10.9)*~~ **(7.4 -- 10.9)**63.8UMEC/VI41387.6 ~~*(6.4, 9.0)*~~ **(6.4 -- 9.0)**53.9t~max~ (h)^b^FF/UMEC/VI43430.1 ~~*(0.1, 0.2)*~~ **(0.1, 0.3)**NAFF/VI42420.1 (0.1, 0.3)NAUMEC/VI41410.1 (0.1, 0.3)NAt~last~ (h)^b^FF/UMEC/VI4343~~*12.0*~~ **12.1** (4.0, 24.1)NAFF/VI424212.0 (4.0, 24.2)NAUMEC/VI414112.0 (2.0, 24.0)NA[^5]

Table 4b.VI plasma PK summary in study 2 (200587).ParameterTreatment^a^NnGeometric mean\
(95% CI)%CVbAUC~(0--6)~ (h×pg/mL)FF/UMEC(500)/VI4444423 (402 -- 445)17.0FF/UMEC(250)/VI4343403 (379 -- 428)20.0FF/VI4343408 (384 -- 433)19.8UMEC(250)/VI4343371 (347 -- 396)21.9AUC~(0--t)~ (h×pg/mL)FF/UMEC(500)/VI4444498 ~~*(449 -- 464)*~~ **(464 -- 534)**23.4FF/UMEC(250)/VI4343488 ~~*(398 -- 467)*~~ **(449 -- 531)**27.5FF/VI4343507 ~~*(531 -- 534)*~~ **(467 -- 551)**27.3UMEC(250)/VI4343436 ~~*(478 -- 551)*~~ **(398 -- 478)**30.5C~max~ (pg/mL)FF/UMEC(500)/VI4444696 ~~*(580 -- 646)*~~ **(646 -- 749)**24.7FF/UMEC(250)/VI4343638 ~~*(482 -- 549)*~~ **(580 -- 701)**31.4FF/VI4343601 ~~*(701 -- 749)*~~ **(549 -- 658)**30.1UMEC(250)/VI4343529 ~~*(581 -- 658)*~~ **(482 -- 581)**30.9t~1/2~ (h)^~~*b*~~^FF/UMEC(500)/VI44194.5 ~~*(3.5, 5.7)*~~ **(3.5 -- 5.7)**53.0FF/UMEC(250)/VI43204.8 ~~*(3.6, 6.4)*~~ **(3.6 -- 6.4)**65.9FF/VI43184.9 ~~*(4.0, 5.9)*~~ **(4.0 -- 5.9)**39.7UMEC(250)/VI43194.7 ~~*(3.6, 6.2)*~~ **(3.6 -- 6.2)**61.9t~max~ (h)^b^FF/UMEC(500)/VI44440.1 (0.1, 0.2)NAFF/UMEC(250)/VI43430.1 (0.1, 0.2)NAFF/VI43430.1 (0.1, 0.2)NAUMEC(250)/VI43430.1 (0.1, 0.2)NA[^6]

###### Pharmacodynamic assessments in study 1 (CTT116415).

  Parameters                                                 Change from baseline in weighted mean (0 -- 4 hours)   Treatment comparison (test vs. reference)                                
  ---------------------------------------------------------- ------------------------------------------------------ ------------------------------------------- ---------------------------- ----------
  Maximum change from baseline in heart rate (bpm)           Test                                                   18.9                                        18.9                         18.9
  Reference                                                  19.1                                                   17.5                                        5.2                          
  Difference (95% CI)                                        --0.2 (--2.6 -- 2.1)                                   1.4 (--0.9 -- 3.7)                          13.6 (11.3 -- 15.9)          
  Derived heart rate (bpm)                                   Test                                                   6.18                                        6.18                         6.18
  Reference                                                  6.08                                                   5.97                                        0.69                         
  Difference (95% CI)                                        0.10 (--1.16 -- 1.35)                                  0.20 (--1.05 -- 1.46)                       5.49 (4.25 -- 6.73)          
  Minimum change from baseline in serum potassium (mmol/L)   Test                                                   --0.30                                      --0.30                       --0.30
  Reference                                                  --0.37                                                 --0.36                                      --0.24                       
  Difference (95% CI)                                        0.06 (--0.01 -- 0.14)                                  0.05 (--0.02 -- 0.13)                       --0.06 (--0.13 -- 0.01)      
  Derived serum potassium (mmol/L)                           Test                                                   --0.123                                     --0.123                      --0.123
  Reference                                                  --0.174                                                --0.185                                     --0.062                      
  Difference (95% CI)                                        0.051 (--0.022 -- 0.124)                               0.063 (--0.010 -- 0.136)                    --0.061 (--0.133 -- 0.012)   
  Maximum change from baseline in blood glucose (mmol/L)     Test                                                   0.544                                       0.544                        0.544
  Reference                                                  0.507                                                  0.452                                       0.061                        
  Difference (95% CI)                                        0.037 (--0.044 -- ~~*0.110*~~ **0.117**)               0.092 (0.011 -- 0.172)                      0.482 (0.403 -- 0.562)       
  Derived blood glucose (mmol/L)                             Test                                                   --0.0211                                    --0.0211                     --0.0211
  Reference                                                  --0.0478                                               --0.0294                                    --0.1698                     
  Difference (95% CI)                                        0.0267 (--0.0354 -- 0.0889)                            0.0083 (--0.0539 -- 0.0705)                 0.1486 (0.0871 -- 0.2102)    

[^1]: ^a^Total dose as 4 consecutive doses: 400 μg FF, 500 μg UMEC, and 100 μg VI. ^b^Median (min, max). AUC = area under the plasma concentration-time curve; C~max~ = maximum observed plasma concentration; CVb = between subject coefficient of variation; FF = fluticasone furoate; N = total number of subjects who received this study medication, n = number of subjects for whom parameter derived; NA = not applicable; PK = pharmacokinetics; t~1/2~ = terminal phase half-life; t~last~ = time of last measurable concentration; t~max~ = time to C~max~; UMEC = umeclidinium; VI = vilanterol.

[^2]: ^a^Total dose as 4 consecutive doses: 400 μg FF, 500 μg or 250 μg UMEC, and 100 μg VI. ^b^Median (min, max).

[^3]: ^a^Total dose as 4 consecutive doses: 400 μg FF, 500 μg UMEC, and 100 μg VI. ^b^Median (min, max).

[^4]: ^a^Total dose as 4 consecutive doses: 400 μg FF, 500 μg or 250 μg UMEC, and 100 μg VI. ^b^Median (min, max).

[^5]: ^a^Total dose as 4 consecutive doses: 400 μg FF, 500 μg UMEC, and 100 μg VI. ^b^Median (min, max).

[^6]: ^a^Total dose as 4 consecutive doses: 400 μg FF, 500 μg or 250 μg UMEC, and 100 μg VI. ^b^Median (min, max).
